- call +1-201-465-4211
- email sales@mrinsights.biz
Retina is a very sensitive and delicate part of human eye which is responsible for receiving and processing light to convert into neural signals and send to the brain for visual activity. The disorders related to retinal health include age-related macular degeneration, diabetic retinopathy, infectious retinitis, macular edema, macular hole, retinoblastoma, retinal degeneration, retinoschisis and uveitis etc. There are various types of retinal disorders but most of them cause visual symptoms.
Scope of the Report:
The worldwide market for Retinal Drugs and Biologics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Retinal Drugs and Biologics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
ALLERGAN
AbbVie
Alimera Sciences
Janssen Biotech
Swedish Orphan Biovitrum
Roche
Bristol-Myers Squibb
Genzyme
Genentech
OCULAR THERAPEUTIX
Bausch & Lomb
UCBCares
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Age Related Macular Degeneration
Diabetic Retinopathy
Ocular Inflammatory Disease (Uveitis)
Macular Hole
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
There are 15 Chapters to deeply display the global Retinal Drugs and Biologics market.
Chapter 1, to describe Retinal Drugs and Biologics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Retinal Drugs and Biologics, with sales, revenue, and price of Retinal Drugs and Biologics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Retinal Drugs and Biologics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Retinal Drugs and Biologics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Retinal Drugs and Biologics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Retinal Drugs and Biologics Introduction
1.2 Market Analysis by Type
1.2.1 Age Related Macular Degeneration
1.2.2 Diabetic Retinopathy
1.2.3 Ocular Inflammatory Disease (Uveitis)
1.2.4 Macular Hole
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 ALLERGAN
2.1.1 Business Overview
2.1.2 Retinal Drugs and Biologics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 AbbVie
2.2.1 Business Overview
2.2.2 Retinal Drugs and Biologics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AbbVie Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Alimera Sciences
2.3.1 Business Overview
2.3.2 Retinal Drugs and Biologics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Alimera Sciences Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Janssen Biotech
2.4.1 Business Overview
2.4.2 Retinal Drugs and Biologics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Janssen Biotech Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Swedish Orphan Biovitrum
2.5.1 Business Overview
2.5.2 Retinal Drugs and Biologics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Roche
2.6.1 Business Overview
2.6.2 Retinal Drugs and Biologics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Roche Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.2 Retinal Drugs and Biologics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Genzyme
2.8.1 Business Overview
2.8.2 Retinal Drugs and Biologics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Genzyme Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Genentech
2.9.1 Business Overview
2.9.2 Retinal Drugs and Biologics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Genentech Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 OCULAR THERAPEUTIX
2.10.1 Business Overview
2.10.2 Retinal Drugs and Biologics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Bausch & Lomb
2.11.1 Business Overview
2.11.2 Retinal Drugs and Biologics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 UCBCares
2.12.1 Business Overview
2.12.2 Retinal Drugs and Biologics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 UCBCares Retinal Drugs and Biologics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Retinal Drugs and Biologics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Retinal Drugs and Biologics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Retinal Drugs and Biologics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Retinal Drugs and Biologics Manufacturer Market Share in 2017
3.3.2 Top 6 Retinal Drugs and Biologics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Retinal Drugs and Biologics Market Analysis by Regions
4.1 Global Retinal Drugs and Biologics Sales, Revenue and Market Share by Regions
4.1.1 Global Retinal Drugs and Biologics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Retinal Drugs and Biologics Revenue and Market Share by Regions (2013-2018)
4.2 North America Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
4.3 Europe Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
4.5 South America Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
5 North America Retinal Drugs and Biologics by Countries
5.1 North America Retinal Drugs and Biologics Sales, Revenue and Market Share by Countries
5.1.1 North America Retinal Drugs and Biologics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Retinal Drugs and Biologics Revenue and Market Share by Countries (2013-2018)
5.2 United States Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
5.3 Canada Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
5.4 Mexico Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
6 Europe Retinal Drugs and Biologics by Countries
6.1 Europe Retinal Drugs and Biologics Sales, Revenue and Market Share by Countries
6.1.1 Europe Retinal Drugs and Biologics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Retinal Drugs and Biologics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
6.3 UK Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
6.4 France Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
6.5 Russia Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
6.6 Italy Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Retinal Drugs and Biologics by Countries
7.1 Asia-Pacific Retinal Drugs and Biologics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Retinal Drugs and Biologics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Retinal Drugs and Biologics Revenue and Market Share by Countries (2013-2018)
7.2 China Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
7.3 Japan Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
7.4 Korea Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
7.5 India Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
8 South America Retinal Drugs and Biologics by Countries
8.1 South America Retinal Drugs and Biologics Sales, Revenue and Market Share by Countries
8.1.1 South America Retinal Drugs and Biologics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Retinal Drugs and Biologics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
8.3 Argentina Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
8.4 Colombia Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Retinal Drugs and Biologics by Countries
9.1 Middle East and Africa Retinal Drugs and Biologics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Retinal Drugs and Biologics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Retinal Drugs and Biologics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
9.3 UAE Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
9.4 Egypt Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
9.5 Nigeria Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
9.6 South Africa Retinal Drugs and Biologics Sales and Growth Rate (2013-2018)
10 Global Retinal Drugs and Biologics Market Segment by Type
10.1 Global Retinal Drugs and Biologics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Retinal Drugs and Biologics Sales and Market Share by Type (2013-2018)
10.1.2 Global Retinal Drugs and Biologics Revenue and Market Share by Type (2013-2018)
10.2 Age Related Macular Degeneration Sales Growth and Price
10.2.1 Global Age Related Macular Degeneration Sales Growth (2013-2018)
10.2.2 Global Age Related Macular Degeneration Price (2013-2018)
10.3 Diabetic Retinopathy Sales Growth and Price
10.3.1 Global Diabetic Retinopathy Sales Growth (2013-2018)
10.3.2 Global Diabetic Retinopathy Price (2013-2018)
10.4 Ocular Inflammatory Disease (Uveitis) Sales Growth and Price
10.4.1 Global Ocular Inflammatory Disease (Uveitis) Sales Growth (2013-2018)
10.4.2 Global Ocular Inflammatory Disease (Uveitis) Price (2013-2018)
10.5 Macular Hole Sales Growth and Price
10.5.1 Global Macular Hole Sales Growth (2013-2018)
10.5.2 Global Macular Hole Price (2013-2018)
11 Global Retinal Drugs and Biologics Market Segment by Application
11.1 Global Retinal Drugs and Biologics Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Retinal Drugs and Biologics Market Forecast (2018-2023)
12.1 Global Retinal Drugs and Biologics Sales, Revenue and Growth Rate (2018-2023)
12.2 Retinal Drugs and Biologics Market Forecast by Regions (2018-2023)
12.2.1 North America Retinal Drugs and Biologics Market Forecast (2018-2023)
12.2.2 Europe Retinal Drugs and Biologics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Retinal Drugs and Biologics Market Forecast (2018-2023)
12.2.4 South America Retinal Drugs and Biologics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Retinal Drugs and Biologics Market Forecast (2018-2023)
12.3 Retinal Drugs and Biologics Market Forecast by Type (2018-2023)
12.3.1 Global Retinal Drugs and Biologics Sales Forecast by Type (2018-2023)
12.3.2 Global Retinal Drugs and Biologics Market Share Forecast by Type (2018-2023)
12.4 Retinal Drugs and Biologics Market Forecast by Application (2018-2023)
12.4.1 Global Retinal Drugs and Biologics Sales Forecast by Application (2018-2023)
12.4.2 Global Retinal Drugs and Biologics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Retinal Drugs and Biologics Picture
Table Product Specifications of Retinal Drugs and Biologics
Figure Global Sales Market Share of Retinal Drugs and Biologics by Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
